AstraZeneca reported second-quarter earnings that surpassed analyst expectations, with core earnings per share rising 21% to $2.63, though revenue slightly missed forecasts at $15.4 billion. Growth in oncology and rare diseases offset weaker sales from the loss of US exclusivity for diabetes drug Farxiga and challenges in China. The company raised its interim dividend and maintains its full-year guidance for mid-to-high single-digit revenue growth and low double-digit core earnings per share growth. CEO Pascal Soriot acknowledged a recent trial failure but highlighted positive results from other Phase III trials and confidence in the pipeline with over 20 key readouts expected in the next 18 months.
Jefferies maintains a buy rating on AstraZeneca, highlighting that detailed data on its lung drug tozorakimab, due on 8 September, could offset the impact of a failed heart trial. The lung drug targets IL-33, potentially benefiting a broader COPD pat...
Jefferies maintains a buy rating on AstraZeneca, expecting detailed data on its lung drug tozorakimab in September to compensate for a recent heart trial failure. The failed CARDIO-TTRansform study cut $4 billion from forecasts, but Jefferies believe...
Royalty Pharma has acquired a royalty interest from Neurimmune in AstraZeneca’s cliramitug, a Phase 3 drug targeting ATTR-CM, for up to $425 million including $125 million upfront. Cliramitug is designed to remove amyloid deposits in the heart, poten...
President Donald Trump announced that generic drugs imported into the US will continue to have zero tariffs for two more years starting August 1, 2024. After this period, tariffs will rise to 100% for one year and then 200% thereafter. The policy aim...
